374 Discovery of a public HPV16-E6 directed T cell response that is associated with overall and progression free survival

Klaudia A Szymonowicz; Bo Jiang; Laurene Cheung; Weihong Xiao; Alexa J Halliday; Emily Bontekoe; Keiko Akagi; Gregory Lizee; Kellie Smith; Maura Gillison; Nils-Petter Rudqvist

doi:10.1136/jitc-2022-SITC2022.0374

Article info

Regular and Young Investigator Award Abstracts

Cell Therapies

374 Discovery of a public HPV16-E6 directed T cell response that is associated with overall and progression free survival

Free

Authors

Klaudia A Szymonowicz The University of Texas MD Anderson Cancer Center, Houston, TX, USA PubMed articles Google scholar articles
Bo Jiang The University of Texas MD Anderson Cancer Center, Houston, TX, USA PubMed articles Google scholar articles
Laurene Cheung Johns Hopkins School of Medicine, Baltimore, MD, USA PubMed articles Google scholar articles
Weihong Xiao The University of Texas MD Anderson Cancer Center, Houston, TX, USA PubMed articles Google scholar articles
Alexa J Halliday The University of Texas MD Anderson Cancer Center, Houston, TX, USA PubMed articles Google scholar articles
Emily Bontekoe The University of Texas MD Anderson Cancer Center, Houston, TX, USA PubMed articles Google scholar articles
Keiko Akagi The University of Texas MD Anderson Cancer Center, Houston, TX, USA PubMed articles Google scholar articles
Gregory Lizee The University of Texas MD Anderson Cancer Center, Houston, TX, USA PubMed articles Google scholar articles
Kellie Smith Johns Hopkins School of Medicine, Baltimore, MD, USA PubMed articles Google scholar articles
Maura Gillison The University of Texas MD Anderson Cancer Center, Houston, TX, USA PubMed articles Google scholar articles
Nils-Petter Rudqvist The University of Texas MD Anderson Cancer Center, Houston, TX, USA PubMed articles Google scholar articles

Citation

Szymonowicz KA, Jiang B, Cheung L, et al

374 Discovery of a public HPV16-E6 directed T cell response that is associated with overall and progression free survival

Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0374

Publication history

First published November 7, 2022.

Online issue publication

April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password